TABLE 2.

Relapse of BALB/c mice treated with the BPaL or TBI-166+BDQ+PZA regimen

Groupb	Mean log10 CFU count at:			Proportion of mice that relapsed after treatment (% relapse in group) at:a
	D0	W4	W8	W4 (+W12)	W8 (+W12)
Untreated	3.62 ± 0.30 (5/5)
BPaL		Negative	Negative	9/13 (69.23)c	0/15 (0)
TBI-166+BDQ+PZA		Negative	Negative	3/14 (21.43)c,d	0/15 (0)

^aTime points are shown as days (D0) or weeks (W4 or W8) of treatment. The start of the treatment (D0) began 4 weeks after infection with M. tuberculosis H37Rv. Mouse lung and spleen homogenates were cultured on 7H10 plates containing activated carbon at the end of 12 weeks following the discontinuation of the treatment regimen of 4 weeks (W4 + W12) or 8 weeks (W8 + W12). n = 15.

^bDrugs (abbreviations) and doses are as follows: pyrazinamide (PZA), 150 mg/kg; TBI-166, 20 mg/kg; bedaquiline (BDQ), 25 mg/kg; linezolid (LZD), 100 mg/kg; pretomanid (PMD), 100 mg/kg; BPaL, BDQ+PMD+LZD.

^cOne mouse in the TBI-166+BDQ+PZA group and two mice in the BPaL group died due to gavage accidents.

^dP < 0.001.